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Lenalidomide plus bendamustine-rituximab does not
overcome the adverse impact of TP53 mutations in
mantle cell lymphoma
TP53 mutations are associated with significant poorer
outcomes in mantle cell lymphoma (MCL), and new
treatment strategies are highly warranted. Lenalidomide
has shown high efficacy in MCL; however, there is no
knowledge of its effect on TP53 mutated cases. In this
study, we show that the addition of lenalidomide to ben-
damustin-rituximab does not overcome the adverse
impact of TP53 mutations.
The outcome of MCL has been improved markedly
during the past decades; however, the course of the dis-
ease remains highly heterogeneous.1–3 Several biomarkers
have been proposed to stratify patients at diagnosis, i.e.,
morphologic subtype, proliferation index and the MCL
international prognostic index (MIPI), but so far none has
been systematically implemented in treatment stratifica-
tion.4,5
TP53 aberrations are associated with more aggressive
disease and poorer outcome.6,7 In a recently published
study by the Nordic Lymphoma Group (NLG) of younger
patients receiving intensive, cytarabine-containing thera-
py and autologous stem-cell transplantation (ASCT), we
showed that TP53 mutations signified a subgroup of
patients with exceedingly poor outcome, overruling all
other known prognostic markers.8 In addition, Aukema et
al. recently reported similar findings based on p53 pro-
tein  expression by  immunohistochemistry.9 Thus, alter-
native therapeutic strategies are highly warranted in this
subset of patients.
In chronic lymphocytic leukemia (CLL), lenalidomide
maintenance has shown promising response rates in
high-risk patients, including patients with TP53-aberra-
tions.10 The Nordic MCL4 trial, Lena-Berit
(clinicaltrials.gov identifier 00963534), investigated the
additive effect of lenalidomide to bendamustin-rituximab
(LBR) in elderly/frail patients.11 In general, this regimen
was associated with an unexpected high frequency of
toxic events, especially infections, cutaneous events and
secondary malignancies; however, the patient cohort
may still serve to investigate the effect of lenalidomide-
addition to chemo-immunotherapy in subsets of patients.
Thus, in this current study, we investigated the outcomes
of patients from the Nordic MCL4 trial in relation to
common MCL-related, genetic aberrations, with a special
emphasis on the TP53-mutated cases. 
An elaborate description of methods are presented in
the Online Supplementary Data and, furthermore, specific
details on the MCL4 trial and genetic analyses are
described in Albertsson-Lindblad et al.11 and Eskelund et
al.,8 respectively. In brief, 50 patients, >65 years or ≤65
years and unfit for ASCT, were enrolled between 2009
and 2013. The regimen consisted of an induction phase
(weeks 1-24) of six cycles of LBR followed by a mainte-
nance phase of lenalidomide (weeks 25-56) (Online
Supplementary Figure S1).11 Pretreatment DNA samples
[(39 bone marrow (BM) and 7 peripheral blood (PB)] were
selected by availability. MCL was detected in all samples
by either flow cytometry or by a positive MRD marker.
Mutational analysis with targeted NGS was performed
on eight MCL-related genes: ATM, KMT2D, CCND1,
TP53, WHSC1, BIRC3, NOTCH1 and NOTCH2; and
droplet digital Polymerase Chain Reaction (ddPCR) was
used to identify two commonly deleted gene regions,
chr17p13 (TP53) and chr9p21 (CDKN2A).8 The study
was performed in agreement with the Declaration of
Helsinki and was conducted according to the guidelines
for Good Clinical Practice, issued by The International
Conference on Harmonization (ICH). The protocol was
approved by all national Ethical Review Boards. All
patients signed a written informed consent to participate
and to donate/provide samples from peripheral blood,
bone marrow and tissue for biologic studies. The clinical
trial was registered at www.ClinicalTrials.gov
(clinicaltrials.gov identifier 00963534).
Patient characteristics are shown in Online
Supplementary Table S1. In an extended clinical follow up
(median follow up of 47 months compared to 31 months
in our previous report), median overall survival (OS) was
69 months (95% CI 60.4-77.5; n events=23) and median
progression-free survival (PFS) was 42 months (95% CI
28.5-55.5; n events=30) (Figure 1 A-B). Median time to
progression/relapse was 53 months (95% CI 34.1-71.9)
(Figure 1 C). None of the curves showed any sign of a
plateau. At the current update, three additional cases of
second primary malignancies (SPM) have been reported,
making the total number of patients with SPM 9 (18%)
(non-invasive skin cancers not included). 
Baseline DNA samples were available for 46 patients
(39 BM and 7 PB samples). Two samples did not reach
sufficient quality for sequencing, and were only included
in the deletion analyses. TP53 deletions were detected in
9 (20%) patients and CDKN2A deletions in 10 (22%)
patients. Five (11%) patients had both deletions. The
most frequently mutated genes were ATM, detected in 15
(34%) patients, KMT2D in 8 (18%) and TP53 in 6 (14%)
patients (Figure 2, Online Supplementary Table S2). Thus,
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Figure 1. Kaplan-Meier estimates of all patients in the MCL4 trial. Kaplan-Meier plots for (A-C) all patients by intention-to-treat (n=50). OS: overall survival;
PFS:progression-free survival; CIR: cumulative incidence of relapsing or progressive disease.
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the prevalence of all genetic aberrations was comparable
to our recently published study of younger MCL
patients.8
Median OS for the TP53 mutated and unmutated
patients were 25 months (95% CI: 6.6-43.4) and 69
months (95% CI: 67.0-70.7), respectively (P<0.0001),
median PFS were 10 months (95% CI: 0-22.9) and 42
months (95% CI: 21.8-62.2), respectively (P=0.001), and
median time to progression or relapse were 10 months
(95% CI: 0-22.9) and 58 months (95% CI: 35.7-80.3),
respectively (P<0.0001) (Figure 3 A-C). One of the TP53
mutated patients withdrew consent at day 28 and did not
provide permission for further follow up and was hence
censored at this time point. Of the remaining 5 patients,
all progressed or relapsed during the study and none
were alive at the current follow up. At the end of the
induction phase, 3 TP53 mutated patients were respond-
ing, but, of these, 2 patients had progressive disease at
next follow up which was only 1.5 months later during
the lenalidomide maintenance phase. All five patients
had available MRD markers, but none achieved MRD
negativity in both BM and PB at any time during follow-
up evaluation.
Collectively, we show that TP53 mutations retain very
poor prognostic value despite the addition of lenalido-
mide to chemo-immunotherapy. Our findings are in con-
trast to preclinical models on lenalidomide, showing
activity in CLL cell lines, independent of functional status
of p53.12 Furthermore, a clinical study on CLL has sug-
gested activity of lenalidomide maintenance in 
TP53-aberrated patients, albeit so far only reported for
PFS.10 Ruan et al. showed promising response rates of L-R
in MCL; however, data on TP53 status was not includ-
ed.13
A limitation to our study is the high number of treat-
ment terminations related to toxicity. However, among
the 5 TP53mutated patients available for follow up, only
two patients withdrew due to adverse events (after
receiving 7 and 11 cycles of lenalidomide, respectively,
and while still being MRD positive), whereas the other 3
patients withdrew due to progressive disease (PD). Thus,
we believe that our results do reflect the actual lack of
efficacy of lenalidomide in these patients. Obviously,
another drawback is the small cohort size, and thus the
results will need validation in a larger cohort.
Nonetheless, the results certainly argue against lenalido-
mide as the solution to the adverse impact of TP53muta-
tions.
Interestingly, the only TP53 mutated patient who had
a long-lasting response (41 months) harboured a splice-
site mutation which is rare for TP53 (2.4% according to
the IARC TP53 Database). This sort of mutation may
cause only loss-of-function, rather than dominant nega-
tive and oncogenic effects.14 Another patient had a splice-
site TP53mutation as well, but was lost to follow up due
to withdrawal of consent at day 28.
Deletions of TP53 and CDKN2A both showed trends
towards inferior outcomes (Online Supplementary Figure
S2). None of the other mutations analyzed in this study
were associated with impact on outcome (data not shown).
Thus, the combined results are similar to the findings in
our recent report on younger MCL patients,8 that the
impact of TP53mutations overrules other genetic aberra-
tions. The two deleted regions showed significant associ-
ation to outcome in univariate models in our previous
report, but only borderline significance in this present
study. Most likely, this is only a reflection of the smaller
patient cohort, rather than a biologic effect.
A total of 12 patients had a mutation and/or deletion of
TP53, and they displayed significantly poorer outcome,
with a median OS of 25 months (95% CI: 0-57.4,
P=0.065), PFS of 12 months (95% CI: 6.6-17, P=0.016),
and 50% of the patients had progressed/relapsed at 34
months (95% CI: 0.2-67, P=0.031) (Figure 3 D-F).
These data supplement the recently published results
from the Nordic Philemon trial (ibrutinib, lenalidomide
and rituximab) which showed almost similar outcomes
of TP53-mutated and -unmutated patients,15 thus sug-
gesting that the effect of the Philemon regimen on TP53
mutated cases is primarily exerted by ibrutinib, rather
than by lenalidomide (or by the combined action of the
two). Fortunately, novel frontline trials including
Ibrutinib are ongoing (e.g., the European Triangle trial for
younger patients and ENRICH trial for elderly) and will
hopefully elaborate on this issue. 
In conclusion, our study shows that the addition of
lenalidomide to rituximab-bendamustine does not over-
come the negative impact of TP53mutations. Thus, TP53
mutated MCL remains a major challenge, and our results
underline the importance of molecular profiling, includ-
ing TP53 status, in future trials exploring novel agents.
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Figure 2. Overview of genetic aberrations. Overview of genetic landscape for all patients with detected genetic aberrations (n=28). Each row represents a gene,
and each column represents a patient. Colour coding: Dark blue: Copy number alteration, (CNA); Red: missense mutations; Green: frameshift indels; Violet: non-
sense mutations; Orange: splice-site mutations; Light blue: Mutations in the 5 untranslated region (UTR).
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Figure 3. Kaplan-Meier estimates of MCL4 patients according to TP53 aberrations. Kaplan-Meier plots for all patients with available DNA (A-C) according to
presence or absence of TP53 mutations, and (D-F) according to TP53 aberrations (mutations and deletions) or TP53 wildtype (WT). OS: overall survival; PFS:
progression-free survival; CIR: cumulative incidence of relapsing or progressive disease.
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